Patient oriented Research--Colon CA & Cancer Immunology

描述(由申请人提供)：此申请详细说明了体验， 以病人为中心的资质和短期和长期计划 兰德尔·F·霍尔科姆医学博士的研究和指导活动 加州大学欧文分校血液学/肿瘤学 赵氏家族综合癌症中心临床研究主任。 自1989年完成血液学/肿瘤学分科培训以来， 霍尔科姆博士在临床和翻译方面建立了学术生涯 以患者为中心的研究，包括临床和基础研究 肿瘤学、免疫学和遗传学领域。他已经成功地在 进行临床/转化性试验并获得校外支持 为这些活动做准备。目前和过去几年，他还 积极指导新手临床研究人员。此应用程序 为以患者为中心的研究中的职业生涯中期研究员奖将提供 支持霍尔科姆博士继续开展和扩大这些活动。 这份申请将概述拟议的研究和指导活动， 对这些活动的机构支持，并记录 霍尔科姆博士致力于以患者为中心的研究事业。 这是职业生涯中期调查员奖的第二次修订 以患者为中心的研究(K24)最初提交了10/1/98，第一个 已提交修订版本7/1/1999。在回答问题时作出重大修改 第一次简要说明中提出的问题已列入第一次订正中。 虽然在第二个摘要中注意到对该提案的批评微乎其微 语句中，进一步加强应用程序的其他信息具有 已在第二次修订的准备过程中提供。

DESCRIPTION (provided by applicant): This application details the experience, qualifications and short- and long-term plans for the patient-oriented research and mentoring activities of Randall F. Holcombe, MD, Chief of Hematology/Oncology at the University of California, Irvine and Associate Director for Clinical Research of the Chao Family Comprehensive Cancer Center. Since completion of Hematology/Oncology sub-specialty training in 1989, Dr. Holcombe has established an academic career in clinical and translational patient-oriented research involving both clinical and basic investigations in the areas of oncology, immunology and genetics. He has been successful in conducting clinical/translational trials and in obtaining extramural support for these activities. Currently and over the past several years, he has also been active in mentoring beginning clinical investigators. This application for the Midcareer Investigator Award in Patient-Oriented Research will provide support to allow Dr. Holcombe to continue and expand upon these activities. This application will outline proposed research and mentoring activities, institutional support for these activities, and documentation of Dr. Holcombe's commitment to a career in patient-oriented research. This is a second revision of a Midcareer Investigator Award in Patient-Oriented Research (K24) initially submitted 10/1/98, with a first revision submitted 7/1/99. Substantial modifications in response to questions raised in the first summary statement were included in the first revision. While minimal criticisms of the proposal were noted in the second summary statement, additional information that further strengthens the application has been provided in preparation of this second revision.